Biohaven Ltd. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Biohaven signed an exclusive global license deal with SK Biopharmaceuticals for opakalim (Kv7 activator for epilepsy). SK Biopharmaceuticals pays $350M upfront at closing plus $50M one year after, up to $150M in development/regulatory milestones, and mid-teens to low-twenties tiered royalties on US opakalim sales (mid-single-digit outside US). Closing expected December 3, 2026. SK assumes ~$245M in additional milestones to Knopp (separate from payments to Biohaven) and go-forward program costs.
Why this rating
~$400M upfront is ~40% of Biohaven's $1B market cap—material near-term financing. However, opakalim faced FDA partial clinical hold Sept 2026 due to metabolite safety concerns. Deal validates asset but removes clinical risk from Biohaven; substantial but qualified by regulatory headwinds.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.